Combination of HLA-DR on
Adult
Aged
Antigens, Bacterial
/ immunology
Cohort Studies
Diagnosis, Differential
Diagnostic Tests, Routine
/ methods
Female
HLA-DR Antigens
/ immunology
Humans
Interferon-gamma
/ immunology
Latent Tuberculosis
/ diagnosis
Leukocytes, Mononuclear
/ immunology
Male
Middle Aged
Mycobacterium tuberculosis
/ immunology
Phytohemagglutinins
/ immunology
ROC Curve
Tuberculosis
/ diagnosis
Tumor Necrosis Factor-alpha
/ immunology
HLA-DR
Mycobacterium tuberculosis-specific cells
TBAg/PHA ratio
active tuberculosis
discrimination
latent tuberculosis infection
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
08
2021
accepted:
11
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
15
2
2022
Statut:
epublish
Résumé
Novel approaches for tuberculosis (TB) diagnosis, especially for distinguishing active TB (ATB) from latent TB infection (LTBI), are urgently warranted. The present study aims to determine whether the combination of HLA-DR on Between June 2020 and June 2021, participants with ATB and LTBI were recruited from Tongji Hospital (Qiaokou cohort) and Sino-French New City Hospital (Caidian cohort), respectively. The detection of HLA-DR on MTB-specific cells upon TB antigen stimulation and T-SPOT assay were simultaneously performed on all subjects. A total of 116 (54 ATB and 62 LTBI) and another 84 (43 ATB and 41 LTBI) cases were respectively enrolled from Qiaokou cohort and Caidian cohort. Both HLA-DR on IFN-γ The combination of HLA-DR on MTB-specific cells and TBAg/PHA ratio could serve as a robust tool to determine TB disease states.
Sections du résumé
Background
Novel approaches for tuberculosis (TB) diagnosis, especially for distinguishing active TB (ATB) from latent TB infection (LTBI), are urgently warranted. The present study aims to determine whether the combination of HLA-DR on
Methods
Between June 2020 and June 2021, participants with ATB and LTBI were recruited from Tongji Hospital (Qiaokou cohort) and Sino-French New City Hospital (Caidian cohort), respectively. The detection of HLA-DR on MTB-specific cells upon TB antigen stimulation and T-SPOT assay were simultaneously performed on all subjects.
Results
A total of 116 (54 ATB and 62 LTBI) and another 84 (43 ATB and 41 LTBI) cases were respectively enrolled from Qiaokou cohort and Caidian cohort. Both HLA-DR on IFN-γ
Conclusions
The combination of HLA-DR on MTB-specific cells and TBAg/PHA ratio could serve as a robust tool to determine TB disease states.
Identifiants
pubmed: 34858413
doi: 10.3389/fimmu.2021.761209
pmc: PMC8632229
doi:
Substances chimiques
Antigens, Bacterial
0
HLA-DR Antigens
0
Phytohemagglutinins
0
Tumor Necrosis Factor-alpha
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
761209Informations de copyright
Copyright © 2021 Luo, Xue, Tang, Lin, Song, Liu, Yin, Huang, Wei, Mao, Wang and Sun.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2021 Feb 04;11:626049
pubmed: 33613569
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32780727
Front Immunol. 2021 Apr 19;12:641378
pubmed: 33953714
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1556-1565
pubmed: 33406011
J Infect. 2009 Dec;59(6):421-3
pubmed: 19766135
Front Med (Lausanne). 2020 Apr 15;7:119
pubmed: 32351964
Front Immunol. 2021 Feb 26;12:607827
pubmed: 33717089
Int J Tuberc Lung Dis. 2016 Apr;20(4):487-93
pubmed: 26970158
Eur Respir J. 2018 Mar 22;51(3):
pubmed: 29567725
J Infect. 2020 Jul;81(1):72-80
pubmed: 32330522
Tuberculosis (Edinb). 2016 May;98:30-41
pubmed: 27156616
Tuberculosis (Edinb). 2020 Dec;125:101992
pubmed: 32957053
Chin Med J (Engl). 2018 Feb 5;131(3):268-275
pubmed: 29363640
Front Cell Infect Microbiol. 2021 Mar 18;11:650163
pubmed: 33816355
Clin Infect Dis. 2021 Sep 7;73(5):793-801
pubmed: 34492697
Front Immunol. 2021 Feb 25;12:639174
pubmed: 33717190
Nat Med. 2011 Mar;17(3):372-6
pubmed: 21336285
Front Immunol. 2018 Sep 28;9:2247
pubmed: 30323818
Lancet Respir Med. 2020 Apr;8(4):407-419
pubmed: 32178775
Front Immunol. 2021 Feb 24;12:608846
pubmed: 33732236
EBioMedicine. 2021 Feb;64:103233
pubmed: 33610126
J Clin Invest. 2015 May;125(5):1827-38
pubmed: 25822019
Int J Clin Pract. 2021 Apr;75(4):e13831
pubmed: 33175465
Front Immunol. 2019 Dec 18;10:2948
pubmed: 31921195
Int J Infect Dis. 2019 Oct;87:21-29
pubmed: 31301458
Lancet Infect Dis. 2013 Apr;13(4):362-72
pubmed: 23531389
Front Immunol. 2020 Sep 10;11:2006
pubmed: 33013856
Thorax. 2019 Dec;74(12):1161-1167
pubmed: 31611342
Front Immunol. 2020 Jul 14;11:1470
pubmed: 32760401
Front Immunol. 2018 Jun 25;9:1481
pubmed: 29983703
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Diagn Microbiol Infect Dis. 2011 Oct;71(2):139-43
pubmed: 21840675
Int J Infect Dis. 2020 Aug;97:190-196
pubmed: 32497795
Clin Chim Acta. 2018 Apr;479:74-78
pubmed: 29325798
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810